Pathogenics, Inc. in-licenses its experimental drugs, demonstrates they work in small-scale human clinical trials, and then partners with large pharmaceutical companies who are seeking new drugs to fill their product pipelines. These partners then complete larger-scale clinical trials, obtain US FDA new drug approval, and market the drugs worldwide. This business strategy is designed to minimize fixed costs, add significant value to our experimental drugs, and accelerate the time to corporate profitability.


Key Pathogenics Investment Points
Pathogenics’ initial therapeutic focus is developing novel therapeutic compounds that treat widespread diseases without promoting drug resistance. This has the following advantages:

• Billion Dollar Market Opportunities with unmet medical needs such as anti-infective therapies that do not promote drug resistance.
• In-Licensing and Big Pharma Partnering minimizes fixed costs and accelerates the time to profitability.
• Clear Exit Strategy first shows the drugs work effectively in humans, then partners with large pharmaceutical companies to perform larger trials, obtains new drug approval and markets them worldwide.
• Experienced Management Team with proven track records in developing and licensing new drugs.